Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of chronic headache with anti-CGRP antibody treatment in idiopathic intracranial hypertension
2025-524822-16-00Phase 3Authorised
- Sponsor
- Rigshospitalet
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of anti-CGRP antibody in idiopathic intracranial hypertension (IIH) and chronic daily headache (CDH), sponsored by Rigshospitalet. Planned start Apr 2026; status: authorised.
02
Drugs
anti-CGRP antibody
03
Conditions
idiopathic intracranial hypertension (IIH)chronic daily headache (CDH)
Beyond the preview
Go deeper on 2025-524822-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524822-16-00.